Literature DB >> 21354147

Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.

Dongdong Lu1, Chang Han, Tong Wu.   

Abstract

BACKGROUND & AIMS: Microsomal prostaglandin E synthase-1 (mPGES-1) is a rate-limiting enzyme that is coupled with cyclooxygenase (COX)-2 in the synthesis of prostaglandin E2. Although COX-2 is involved in the development and progression of various human cancers, the role of mPGES-1 in carcinogenesis has not been determined. We investigated the role of mPGES-1 in human cholangiocarcinoma growth.
METHODS: We used immunohistochemical analyses to examine the expression of mPGES-1 in formalin-fixed, paraffin-embedded human cholangiocarcinoma tissues. The effects of mPGES-1 on human cholangiocarcinoma cells were determined in vitro and in SCID mice. Immunoblotting and immunoprecipitation assays were performed to determine the levels of PTEN and related signaling molecules in human cholangiocarcinoma cells with overexpression or knockdown of mPGES-1.
RESULTS: mPGES-1 is overexpressed in human cholangiocarcinoma tissues. Overexpression of mPGES-1 in human cholangiocarcinoma cells increased tumor cell proliferation, migration, invasion, and colony formation; in contrast, RNA interference knockdown of mPGES-1 inhibited tumor growth parameters. In SCID mice with tumor xenografts, mPGES-1 overexpression accelerated tumor formation and increased tumor weight (P<.01), whereas mPGES-1 knockdown delayed tumor formation and reduced tumor weight (P<.01). mPGES-1 inhibited the expression of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), leading to activation of the epidermal growth factor/phosphoinositide 3-kinase/AKT/mammalian target of rapamycin signaling pathways in cholangiocarcinoma cells. mPGES-1-mediated inhibition of PTEN is regulated through blocking of early growth response-1 sumoylation and binding to the 5'-untranslated region of the PTEN gene.
CONCLUSIONS: mPGES-1 promotes experimental cholangiocarcinogenesis and tumor progression by inhibiting PTEN.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21354147      PMCID: PMC3109169          DOI: 10.1053/j.gastro.2011.02.056

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  42 in total

1.  Vioxx withdrawal alarms cancer prevention researchers.

Authors:  Cori Vanchieri
Journal:  J Natl Cancer Inst       Date:  2004-12-01       Impact factor: 13.506

2.  Clinical trials. Nail-biting time for trials of COX-2 drugs.

Authors:  Jennifer Couzin
Journal:  Science       Date:  2004-12-03       Impact factor: 47.728

Review 3.  Cholangiocarcinoma.

Authors:  Konstantinos N Lazaridis; Gregory J Gores
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

Review 4.  Mechanisms and consequences of activation of protein kinase B/Akt.

Authors:  J Downward
Journal:  Curr Opin Cell Biol       Date:  1998-04       Impact factor: 8.382

5.  The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.

Authors:  T Maehama; J E Dixon
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

6.  Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target.

Authors:  P J Jakobsson; S Thorén; R Morgenstern; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

Review 7.  Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.

Authors:  Alphonse E Sirica
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

Review 8.  The molecular pathogenesis of cholangiocarcinoma.

Authors:  Eric P Berthiaume; Jack Wands
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

Review 9.  The epidemiology of cholangiocarcinoma.

Authors:  Yasser Shaib; Hashem B El-Serag
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

10.  Analysis of the glutathione S-transferase (GST) gene family.

Authors:  Daniel W Nebert; Vasilis Vasiliou
Journal:  Hum Genomics       Date:  2004-11       Impact factor: 4.639

View more
  12 in total

Review 1.  PTEN function: the long and the short of it.

Authors:  Benjamin D Hopkins; Cindy Hodakoski; Douglas Barrows; Sarah M Mense; Ramon E Parsons
Journal:  Trends Biochem Sci       Date:  2014-03-18       Impact factor: 13.807

2.  Microsomal prostaglandin E synthase-1 protects against Fas-induced liver injury.

Authors:  Lu Yao; Weina Chen; Chang Han; Tong Wu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-04-21       Impact factor: 4.052

3.  The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.

Authors:  Wenbo Ma; Chang Han; Jinqiang Zhang; Kyoungsub Song; Weina Chen; Hyunjoo Kwon; Tong Wu
Journal:  Hepatology       Date:  2020-10-09       Impact factor: 17.425

4.  Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression.

Authors:  Lu Yao; Chang Han; Kyoungsub Song; Jinqiang Zhang; Kyu Lim; Tong Wu
Journal:  Cancer Res       Date:  2015-02-17       Impact factor: 12.701

Review 5.  PTEN modulators: a patent review.

Authors:  Chandra S Boosani; Devendra K Agrawal
Journal:  Expert Opin Ther Pat       Date:  2013-02-05       Impact factor: 6.674

6.  WTAP regulates migration and invasion of cholangiocarcinoma cells.

Authors:  Hong-Jae Jo; Hye-Eun Shim; Myoung-Eun Han; Hyun-Jung Kim; Ki-Sun Kim; Sungmin Baek; Kyung-Un Choi; Gi-Yeong Hur; Sae-Ock Oh
Journal:  J Gastroenterol       Date:  2013-01-25       Impact factor: 7.527

7.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

Review 8.  Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma.

Authors:  Samuele De Minicis; Tatiana Kisseleva; Heather Francis; Gianluca Svegliati Baroni; Antonio Benedetti; David Brenner; Domenico Alvaro; Gianfranco Alpini; Marco Marzioni
Journal:  Dig Liver Dis       Date:  2012-11-22       Impact factor: 4.088

9.  PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression.

Authors:  Jurairat Jongthawin; Porncheera Chusorn; Anchalee Techasen; Watcharin Loilome; Thidarut Boonmars; Raynoo Thanan; Anucha Puapairoj; Narong Khuntikeo; Wichittra Tassaneeyakul; Puangrat Yongvanit; Nisana Namwat
Journal:  Tumour Biol       Date:  2014-05-18

10.  Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis.

Authors:  Federica Finetti; Erika Terzuoli; Elena Bocci; Isabella Coletta; Lorenzo Polenzani; Giorgina Mangano; Maria Alessandra Alisi; Nicola Cazzolla; Antonio Giachetti; Marina Ziche; Sandra Donnini
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.